Cogstate Lunch & Learn Series

Cognitive endpoints for Preclinical Alzheimer's disease

On-demand Recording


At this lunch & learn in Chicago, Cogstate Chief Science Officer, Prof Paul Maruff, discussed cognitive endpoints for studies of preclinical Alzheimer's disease.

Professor Paul Maruff is a founder of Cogstate and is a neuropsychologist with expertise in the measurement of subtle behavioral and cognitive dysfunction in neuropsychiatric and neurological disease and disorders.  Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods, neuroimaging, genetics and clinical assessment in to guide decision making in about brain function in both clinical medicine in drug development. 

Paul has worked extensively to develop methods for identification of the nature and magnitude of cognitive impairment, and to assess the efficacy of licensed and experimental drugs and procedures, in Alzheimer’s disease, mild cognitive impairment and the HIV dementia complex. He has extended these methods to the identification of cognitive dysfunction and the effects of treatment in psychiatric diseases such as schizophrenia, attention deficit disorder and obsessive-compulsive disorder, major depressive disorder and substance abuse in adults and children.

In addition to being responsible for the scientific progress at Cogstate, Paul is also appointed Professor at the Florey Institute for Neuroscience and Mental Health where is an active member of the Alzheimer’s disease research group.  He is currently clinical co-chair of the clinical committee in the Australian Imaging Biomarkers and Lifestyle (AIBL) study and also sits on the executive committee for that group.  Paul has published over 300 research articles in international peer-reviewed scientific journals and has co-authored 10 book chapters.